Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: A retrospective cohort study

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Iliodromiti, Stamatina ^a   Lan, Vuong Thi Ngoc ^b,d   Tuong, Ho Manh ^c,d   Tuan, Phung Huy ^d   Humaidan, Peter ^e,f   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^c VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^d IVFAS   (Viet Nam)

^e SKIVE REGIONAL HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

GnRH agonist; GnRH antagonist; Live birth; Luteal support; Ovarian hyperstimulation syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; STEROID;

ADULT; ARTICLE; ASIAN; BIRTH RATE; BLOATING; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM; EPIGASTRIC PAIN; FEMALE; HUMAN; INCIDENCE; LIVE BIRTH; LUTEAL PHASE; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OUTCOME ASSESSMENT; OVARIAN RESERVE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SPONTANEOUS ABORTION;

EID: 84890933803     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-93     Document Type: Article

References (40)

1. Induction of preovulatory luteinizing-hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing-hormone agonist. Itskovitz J, Erlik Y, Boldes R, Kahana L, Levron J, Brandes JM, Fertil Steril 1991 56 213 220 1906406
2. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Itskovitz-Eldor J, Kol S, Mannaerts B, Hum Reprod 2000 15 1965 1968 10.1093/humrep/15.9.1965 10966996
3. Hormonal dynamics at midcycle- a reevaluation. Hoff JD, Quigley ME, Yen SSC, J Clin Endocrinol Metab 1983 57 792 796 10.1210/jcem-57-4-792 6411753
4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC, J Clin Endocrinol Metab 2003 88 4186 4192 10.1210/jc.2002-021953 12970285
5. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G, Hum Reprod 2005 20 2887 2892 10.1093/humrep/dei150 15979994
6. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY, Hum Reprod 2005 20 1213 1220 10.1093/humrep/deh765 15760966
7. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Pirard C, Donnez J, Loumaye E, Hum Reprod 2006 21 1894 1900 10.1093/humrep/del072 16556673
8. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Humaidan P, Bungum L, Bungum M, Andersen CY, Reprod Biomed Online 2006 13 173 178 10.1016/S1472-6483(10)60612-8 16895629
9. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY, Fertil Steril 2010 93 847 854 10.1016/j.fertnstert.2008.12.042 19200959
10. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Humaidan P, Reprod Biomed Online 2009 18 630 634 10.1016/S1472-6483(10)60006-5 19549440
11. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY, Hum Reprod 2013 28 2511 2521 10.1093/humrep/det249 23753114
12. Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T, Hum Reprod 2006 21 1260 1265 10.1093/humrep/dei475 16439507
13. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C, Fertil Steril 2008 89 84 91 10.1016/j.fertnstert.2007.02.002 17462639
14. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Fertil Steril 2011 95 2715 2717 10.1016/j.fertnstert.2011.03.109 21550042
15. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R, Hum Reprod 2012 27 753 759 10.1093/humrep/der463 22252086
16. Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Orvieto R, Reprod Biomed Online 2012 24 680 681 author reply 682-683 10.1016/j.rbmo.2012.03.005 22503268
17. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L, Fertil Steril 2011 96 63 68 10.1016/j.fertnstert.2011.04.050 21565337
18. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A, Hum Reprod 2011 26 1768 1774 10.1093/humrep/der106 21558332
19. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, Devroey P, Fertil Steril 2003 79 873 880 10.1016/S0015-0282(02)04920-8 12749423
20. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Humaidan P, Quartarolo J, Papanikolaou EG, Fertil Steril 2010 94 389 400 10.1016/j.fertnstert.2010.03.028 20416867
21. RCOG, The management of ovarian hyperstimulation syndrome London: Royal College of Obstetricians and Gynaecologists 2006
22. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM, Hum Reprod Update 2006 12 159 168 16254001
23. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, Khattab SM, Van Wely M, Cochrane Database Syst Rev 2011 19 D008046
24. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K, Hum Reprod 2013 28 1077 1083 10.1093/humrep/det015 23377771
25. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Humaidan P, Kol S, Papanikolaou EG, Hum Reprod Update 2011 17 510 524 10.1093/humupd/dmr008 21450755
26. Hormonal profiles in the follicular phase, luteal phase and first trimester of pregnancies arising from in-vitro fertilization. Yovich JL, Stanger JD, Yovich JM, Tuvik AI, Turner SR, Br J Obstet Gynaecol 1985 92 374 384 10.1111/j.1471-0528.1985.tb01112.x 2580551
27. Luteal phase support for assisted reproduction cycles. Van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M, Cochrane Database Syst Rev 2011 5 D009154
28. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L, Fertil Steril 2012 97 1316 1320 10.1016/j.fertnstert.2012.03.015 22480822
29. Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology. Purcell K, Schembri M, Frazier LM, Rall MJ, Shen S, Croughan M, Grainger DA, Fujimoto VY, Fertil Steril 2007 87 297 302 10.1016/j.fertnstert.2006.06.031 17081529
30. Asian ethnicity in anonymous oocyte donors is associated with increased estradiol levels but comparable recipient pregnancy rates compared with Caucasians. Huddleston HG, Rosen MP, Lamb JD, Modan A, Cedars MI, Fujimoto VY, Fertil Steril 2010 94 2059 2063 10.1016/j.fertnstert.2009.11.019 20056204
31. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin- releasing hormone antagonist protocol in combination with a "freeze- all" strategy: a prospective multicentric study. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S, Fertil Steril 2011 95 2029 U2195 10.1016/j.fertnstert.2011.01.163 21371705
32. GnRH agonist triggering: recent developments. Kol S, Humaidan P, Reprod BioMed Online 2013 26 226 230 10.1016/j.rbmo.2012.11.002 23337420
33. Distinction between early and late ovarian hyperstimulation syndrome. Mathur RS, Akande AV, Keay SD, Hung LP, Jenkins JM, Fertil Steril 2000 73 901 907 10.1016/S0015-0282(00)00492-1 10785214
34. Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. Lawlor DA, Nelson SM, Lancet 2012 379 521 527 10.1016/S0140-6736(11)61267-1 22243709
35. An OHSS-Free Clinic by segmentation of IVF treatment. Devroey P, Polyzos NP, Blockeel C, Hum Reprod 2011 26 2593 2597 10.1093/humrep/der251 21828116
36. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. Nelson SM, Lawlor DA, PLoS Med 2011 8 1000386 10.1371/journal.pmed. 1000386 21245905
37. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J, Fertil Steril 2003 79 5 1123 1128 10.1016/S0015-0282(03) 00177-8 12738506
38. New algorithm for OHSS prevention. Papanikolaou EG, Humaidan P, Polyzos N, Kalantaridou S, Kol S, Benadiva C, Tournaye H, Tarlatzis B, Reprod Biol Endocrinol 2011 9 147 10.1186/1477-7827-9-147 22054506
39. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, Ziebe S, Hald F, Hauge B, Toft B, Hum Reprod 2002 17 357 361 10.1093/humrep/17.2.357 11821278
40. Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Schmidt KL, Ziebe S, Popovic B, Lindhard A, Loft A, Andersen AN, Fertil Steril 2001 75 337 341 10.1016/S0015-0282(00)01709-X 11172836